IL2 and hereditary clear cell renal cell carcinoma: Finkelstein and colleagues reported that high DC/MDSC ratios and low pretreatment MDSC levels could predict response to high-dose IL-2 therapy in patients with melanoma and renal cell carcinoma [39].